Global Organ Transplant Immunosuppressant Drugs Market: Key Trends  

Organ transplantation is slowly emerging as an effective method for the treatment of end-stage organ failure. Due to the increasing incidence of chronic ailments, the demand for organ replacement has risen considerably around the world. This subsequently fuels demand for advanced immunosuppressant drugs to prevent organ rejection post transplantation.

Despite recent advances in medical science, post-operative complications are still a major challenge that the global organ replacement immunosuppressant drugs market needs to address. The long-standing inadequate medical coverage for immunosuppressant drugs can compromise the quality of care offered to patients suffering from organ failure. According to Transparency Market Research (TMR), this factor will translate into negative growth for the global organ transplant immunosuppressant drugs market from 2015 to 2023.

Besides this, the high cost of organ transplantation and the advent of stem cell therapies are limiting the market’s trajectory. The global organ transplant immunosuppressant market stood at US$5.1 bn in 2014. Exhibiting a CAGR of -5.0% between 2015 and 2023, the market’s valuation is expected to reach US$3.2 bn by the end of 2023.

Use of Immunosuppressant Drugs during Kidney Transplantation to Significantly Increase

Based on transplant, the demand for immunosuppressant drugs used during kidney transplantation was the highest in 2014. In the last couple of years, kidney transplantation has emerged as the most preferred treatment method for end-stage renal diseases. It has proven more cost-effective than prolonged periods of dialysis. Hence, TMR projects the demand for kidney replacement procedures to rise at a considerable pace during the forecast period. This will in turn will boost demand for immunosuppressant drugs from the segment, which held over 53.4% of the market in 2014. The kidney transplant segment is expected to maintain its dominance in the market through the forecast period.

Furthermore, the market is expected to witness demand from the bone marrow transplant segment as novel immunosuppressant drugs are developed for the treatment of graft-versus-host diseases. The use of these drugs is also expected to increase during liver, heart, and lung transplants.

Robust Healthcare Infrastructure Fuels Demand for Immunosuppressant Drugs from North America

Regionally, North America led the global organ immunosuppressant drugs market with a share of 46.2% in 2014. The region exhibits high demand for immunosuppressant drugs due to the higher number of organ transplantations conducted therein. According to TMR, North America is expected to report the fastest growth due to the increasing number of successful organ replacement surgeries conducted in the region. This will in turn bolster demand for advanced immunosuppressant therapeutics.  

Europe emerged as the second largest market for immunosuppressant drugs in the same year. These two regions will continue to lead the global market due to the recent improvements in surgical techniques, technology, and immunosuppressant drug discovery. The robust healthcare infrastructure in North America and Europe will seal the dominance of these regions in the global market.

Novartis AG, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Sanofi are some of the most prominent companies operating in the market.

This report on the organ transplant immunosuppressant drugs market studies the current and future prospects of the global market. Organ transplant immunosuppressant drugs market are prescribed to patients during or after transplant of organs such as kidney, liver, heart, lung and bone marrow. Organ dysfunction caused due to severe injuries, cancer, organ failure and/or genetic disorders necessitate the requirement for organ transplant procedures.  Thus, rise in the number of organ transplants across the globe, along with advancements in the immunosuppressant drugs are expected to propel the global organ transplant immunosuppressant drugs market.

The organ transplant immunosuppressant drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global organ transplant immunosuppressant drugs market with respect to the segments based on the type of drug class, transplant, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global intracranial pressure monitors market.

Based on drug class, the organ transplant immunosuppressant drugs market has been segmented into four major categories: calcineurin inhibitors, antiproliferative agents, mTOR inhibotrs, antibodies and steroids. On the basis of transplant type, the market has been categorized into five segments: kidney, bone marrow, liver, heart, lungs, and others (intestinal and multi-visceral organs). The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global organ transplant immunosuppressant drugs market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, Australia, Rest of Asia Pacific), Latin America (Brazil, Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global organ transplant immunosuppressant drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AbbVie, Inc., Astellas Pharma, Inc., Bristol?Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genzyme Corporation (Sanofi S.A.), GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. and Veloxis Pharmaceuticals A/S.

The global organ transplant immunosuppressant drugs market is segmented as follows:

Global Organ Transplant Immunosuppressant Drugs, by Drug Class

  • Calcineurin Inhibitors
    • Tacrolimus
    • Cyclosporine
  • Antiproliferative Agents
    • Mycophenolate Mofetil
    • Mycophenolate Sodium
    • Azathioprine
  • mTOR Inhibitors
    • Sirolimus
    • Everolimus
  • Antibodies
    • Antithymocyte Globulin
    • Muromonab-CD3
    • Alemtuzumab
    • Rituximab
    • Daclizumab
    • Basiliximab
    • Belatacept
    • Eculizumab
  • Steroids

Global Organ Transplant Immunosuppressant Drugs, by Transplant

  • Kidney
  • Bone Marrow
  • Liver
  • Heart
  • Lungs
  • Others (Intestinal and Multi-visceral Organs)

Global Organ Transplant Immunosuppressant Drugs, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Australia
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Rest of the World

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Organ Transplant Immunosuppressant Drugs

Buy Now